Enzon Extends Rights Plan and Preferred Exchange Offer

The latest announcement is out from Enzon Pharmaceuticals ( (ENZN) ).

On February 27, 2026, Enzon Pharmaceuticals amended its Section 382 Rights Agreement for the eighth time, pushing the final expiration date of the shareholder rights from March 2, 2026 to noon New York time on March 11, 2026, while leaving all other terms unchanged. Management stated that extending the rights plan, which is designed to protect the company’s tax assets by limiting ownership changes, remains in the best interests of Enzon and its stockholders.

Also on February 27, 2026, Enzon announced an extension of its exchange offer to holders of Series C Non-Convertible Redeemable Preferred Stock, who are being offered Enzon common shares in exchange, moving the offer’s expiration to one minute after 11:59 p.m. Eastern on March 9, 2026, unless further extended. The adjustments to both the rights plan and the preferred stock exchange offer come as Enzon advances its planned merger with Viskase Companies, tightening control over its capital structure and ownership profile ahead of the proposed combination.

More about Enzon Pharmaceuticals

Enzon Pharmaceuticals, Inc. is a U.S.-based biopharmaceutical company whose shares trade in the over-the-counter market and which has been focused in recent years on managing its capital structure and strategic transactions rather than active drug commercialization. The company is currently pursuing a merger with Viskase Companies, Inc., which would create a combined entity whose common stock is expected to be quoted on the OTCQB tier, subject to closing conditions and regulatory approvals.

Average Trading Volume: 75,634

Technical Sentiment Signal: Sell

Current Market Cap: $5.27M

See more data about ENZN stock on TipRanks’ Stock Analysis page.